Effect of Bile Acids on GLP-1 Secretion

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to describe the physiological, pathophysiological and potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1) secretion in human glucose homeostasis.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Treatments: Bile Acids and Salts; Chenodeoxycholic Acid; Colesevelam Hydrochloride

Criteria

Patients with type 2 diabetes

Inclusion Criteria:

• danish caucasian ethnicity

• normal haemoglobin

• BMI > 25 kg/m2

• HbA1c < 9%

• informed consent

Exclusion Criteria:

• liver disease(ALT and AST > upper reference limit)

• gastrointestinal disease

• liver and biliary tract disease

• nephropathy (serum creatinine > 150 μM, and/or albuminuria)

• treatment with insulin, glp-1 analogues and/ or DPP-4 inhibitors

• treatment with medicine that can not be paused for 12 hours

• previous abdominal surgery eg. cholecystectomy

• BMI < 18,5 kg/m2 or > 35 kg/m2

Healthy Volunteers

Inclusion Criteria:

• danish caucasian ethnicity

• normal haemoglobin

• HbA1c < 6,0 (American Diabetes Association guidelines)

• informed consent

Exclusion Criteria:

• liver disease(ALT and AST > upper reference limit)

• gastrointestinal disease

• liver and biliary tract disease

• nephropathy (serum creatinine > 150 μM, and/or albuminuria)

• treatment with medicine that can not be paused for 12 hours

• previous abdominal surgery eg. cholecystectomy

• BMI < 18,5 kg/m2 or > 35 kg/m2

• first degree relatives diagnosed with diabetes

• previously diagnosed with diabetes, or treated with antidiabetic agents